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Introduction
Indole-3-carbinol (I3C) is an autolysis product of a glucosinolate, glucobrassicin, found in Brassica sp. or cruciferous vegetables (cabbage, broccoli, cauliflower, and brussels spouts) 1, 2 . In vitro, I3C was found to suppress the proliferation of various tumor cells including breast 3 , prostate 4 , colon 5 , and endometrial cancer cells. In most cells, I3C induces G1/S cell cycle arrest 6 . In vivo, I3C has been shown to suppress tumorigenesis of the colon 7, 8 , lung 9-11 , breast 12 , cervix 13, 14 and liver 15 .
This molecule has been found to be effective clinically in treating precancerous lesions of the cervix and laryngeal papillomas, both of which have a human papillomavirus (HPV) component to there etiologies [16] [17] [18] [19] . I3C has also been shown to alter immune function 7, 20 , inhibit cigarette smoke-induced DNA-adduct formation 21 , and reverse multidrug resistance in vivo. Rats fed I3C daily for 7 wk had significantly reduced natural killer cell activity and elevated T-cell-mediated delayed-type hypersensitivity but no change in antibody production 20 .
Numerous reports indicate that I3C mediates its effects through alteration of gene expression in different cells 22 . This indole downregulates the expression of various genes including inducible nitric oxide synthase (iNOS) 23 , cyclindependent kinase 6 (CDK6) 3, 6 , PSA 24 , and Bcl-2 4 . It has also been shown to inhibit Akt 25 disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter 26 . That I3C directly binds to estrogen receptor-alpha 27-30 , aryl hydrocarbon (Ah) receptor 31 , and androgen receptor 32 has been reported.
Besides antiproliferative and immunomodulatory effects, I3C has also been demonstrated to suppress the invasion and migration of human breast cancer cells 29, 33 .
Although this wide range of activities has been assigned to I3C, its basic mechanism of action remains unclear. Based on the confluence of pathways affected by I3C and NF-κB, we postulated that I3C interferes with the NF-κB activation pathway to exert its effects on gene expression. For example, several genes that mediate proliferation, apoptosis, and metastasis are regulated by NF-κB 34 . This transcription factor is activated by various carcinogens and inflammatory stimuli, including cigarette smoke, TNF, IL-1, receptor of receptor activator of NF-κB ligand (RANKL), phorbol 12-myristate 13-acetate (PMA), and lipopolysaccharide (LPS). NF-κB consists of p50 and p65 heterodimer retained in the cytoplasm by masking NLS by IκBα, the inhibitor. On activation, IκBα kinase (IKK) is activated, leading to IκBα phosphorylation, ubiquitination, and degradation; thus releasing p50-p65 to translocate to the nucleus, bind to its consensus sequence, and induce gene transcription. Although NF-κB activation has been shown to regulate apoptosis and proliferation in leukemic cells [35] [36] [37] , there is no report on the effect of I3C in these cells. Therefore the aim of the current Takada et al 4/4/05 6 study was to investigate the effect of I3C on the NF-κB activation pathway and on apoptosis in leukemic cells.
Materials and Methods
Reagents: I3C was purchased from Sigma-Aldrich (St. Louis, MO). A 50 mM solution was prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich), stored as small aliquots at -20 o C, and then thawed and diluted as needed in cell culture medium as described 4, 6 . No loss of activity of I3C was noted after storage for six months. Throughout 0.1% DMSO (equivalent to 50 µM I3C) was used as control.
Bacteria-derived human recombinant TNF, purified to homogeneity with a specific activity of 5 x 10 7 U/mg was kindly provided by Genentech (South San Francisco, CA). Bacteria-derived human recombinant IL-1β, purified to homogeneity with a specific activity of 1.0 EU/µg was purchased from R&D Systems (Minneapolis, MN Electrophoretic mobility shift assays (EMSA): To measure NF-κB activation, we prepared the nuclear extracts and performed EMSA as described previously 39 . The dried gels were visualized, and radioactive bands quantitated by a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) using Imagequant software.
Western blot analysis:
To determine the levels of protein expression in the cytoplasm or nucleus, we prepared extracts and fractionated them by SDSpolyacrylamide gel electrophoresis (PAGE) as described previously 39 .
IKK assay:
To determine the effect of I3C on IKK activation, IKK assay was performed by a method described previously 39 . Briefly, whole-cell extract was prepared, incubated with anti-IKK-α antibody, and precipitated immunocomplex by protein A/G-Sepharose beads (Pierce, Rockford, IL). Immunocomplex was subjected for kinase assay using GST-IκBα (1-79) as substrate. cotransfected with TNFR1-expressing plasmids, and then NF-κB-dependent SEAP expression was monitored.
NF-κB
Immunoprecipitation of p65 for p65 acetylation: To determine the effect of I3C on TNF-induced acetylation of p65, was examined as described previously 40 . Briefly, whole-cell extract was prepared, incubated with anti-p65 antibody, and precipitated immunocomplex by protein A/G-Sepharose beads. Immunocomplex was subjected for SDS-PAGE, and performed Western blot analysis using antiacetyl-lysine antibody.
Immunocytochemistry for NF-κB p65 localization: The effect of I3C on the nuclear translocation of p65 was examined by immunocytochemistry as described previously 39 . Briefly, cells were fixed with parahormaldehyde, permeabilized with Triton-X 100, blocked with normal goat serum, incubated with rabbit polyclonal anti-p65 antibody, incubated with goat anti-rabbit IgG-Alexa 594 (Molecular Probes, Eugene, OR) and counterstained for nuclei with Hoechst 33342 (SigmaAldrich).
Cytotoxicity assay: The effect of I3C on the cytotoxic effects of TNF was determined by the MTT uptake method as described 41 . Briefly, 5000 cells were seeded in triplicate in a 96-well plate and treated as indicated. Thereafter, an MTT solution was added, lysed, and then the OD was measured at 570 nm.
TUNEL assay:
We also assayed cytotoxicity by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) Live and dead assay: Apoptosis was measured by the Live and Dead assay (Molecular Probes), which determines intracellular esterase activity and plasma membrane integrity, was performed as described previously 39 .
Results
The current study was undertaken to investigate the effect of I3C on the NF-κB activation pathway, on NF-κB-regulated gene expression, and on apoptosis in leukemic cells. The concentration of I3C and NF-κB activators used and the time of exposure had minimal effect on the viability of these cells (data not shown). (Fig. 1A) . These results suggest that the I3C acts at a step in the NF-κB activation pathway that is common to all five agents.
I3C inhibits TNF-dependent NF-κB activation in a time-dependent manner.
Since TNF is one of the most potent activators of NF-κB and the mechanism of activation of NF-κB is relatively well established, we examined the effect of I3C on TNFinduced NF-κB activation. Jurkat cells were incubated with I3C for various times, and then exposed to TNF. I3C by itself did not activate NF-κB but TNF-induced NF-κB activation was inhibited by I3C at 24 h (Fig. 1B) . Under these conditions, cells treated with I3C were fully viable. 44 ], so we also investigated whether I3C
Inhibition of NF-κB activation by I3C is dose-dependent and is
could block TNF-induced NF-κB activation in Jurkat, KBM-5, and H1299 cells.
Cells were pretreated with different concentrations of I3C and then treated with TNF. TNF activated NF-κB in all cell types, and I3C inhibited the activation in a dose-dependent manner (Fig. 1C) . The results also indicate that 50 µM I3C is needed for maximum suppression of NF-κB activation.
I3C inhibits constitutive NF-κB activation in a dose-dependent manner:
Whether I3C could suppress constitutive NF-κB activation was also examined. We treated human multiple myeloma MM.1 and U266, and squamous cell carcinoma SCC-4 cells, which are known to express constitutive active NF-κB 36,37,45 with various concentrations of I3C. Constitutive NF-κB activation was suppressed above 50 µM (Fig. 1D ).
We have shown that high concentrations of TNF induce NF-κB more intensely than lower doses given for long times 46 
I3C inhibits TNF-dependent IκBα degradation.
To determine whether I3C's inhibitory activity was due to inhibition of IκBα degradation, we pretreated cells with I3C, exposed them to TNF for various times, and examined them for NF-κB activation in the nucleus by EMSA and for IκBα status in the cytoplasm by Western blot analysis. NF-κB was progressively activated with increase in incubation times with TNF. The I3C pre-treated cells showed a dramatic decrease in activation of NF-κB even after 60 min of TNF stimulation ( Fig. 2A) .
The translocation of NF-κB to the nucleus is preceded by the proteolytic phosphorylation of IκBα, we determined its effect on TNF-induced IKK activation.
In immune complex kinase assays, TNF activated IKK as early as 5 min after TNF treatment but I3C completely suppressed this activation (Fig. 2E) . Neither TNF nor I3C had any effect on the expression of IKK-α or IKK-β proteins.
To evaluate whether I3C suppresses the IKK activity directly by binding to the IKK protein or by suppressing the activation of IKK, we incubated whole-cell extracts from untreated and TNF-treated cells with various concentrations of I3C.
Immunecomplex kinase assay showed that I3C did not directly bind IKK, suggesting that I3C modulates TNF-induced IKK activation (data not shown).
I3C inhibits TNF-induced nuclear translocation of p65 in lymphoma cells. TNF
induces the phosphorylation of p65, which is required for its transcriptional activity 49 . Following phosphorylation, the p65 subunit is translocated to the nucleus. As shown in Fig. 3A , TNF induced phosphorylation of p65 in a timedependent manner; as early as 5 min after TNF stimulation, p65 was phosphorylated and it levels in the cytoplasm increased up to 30 min. On pretreatment of cells with I3C, TNF failed to induce phosphorylation of p65. We also showed that I3C suppressed TNF-induced nuclear translocation of p65 in a time-dependent manner (Fig. 3B ).
The acetylation of p65 plays a key role in NF-κB transcriptional activity 50 .
To examine the effect of I3C on the acetylation of p65 by TNF, cells were pretreated with I3C and then treated with TNF for the indicated times. Whole-cell extracts were prepared and immunoprecipitated with anti-p65 antibody, and then Western blot analysis was performed using anti-acetyl-lysine antibody. Whereas TNF induced acetylation of p65 in a time-dependent manner, I3C suppressed it (Fig.   3C ).
An immunocytochemistry assay confirmed the effect of I3C on the suppression of nuclear translocation of p65: in untreated cells p65 localized in the cytoplasm, TNF induced its nuclear translocation, and I3C clearly suppressed this traslocation (Fig 3D) . staining methods. I3C enhanced TNF-induced cytotoxicity (Fig. 5A1) , as well as doxorubicin- (Fig. 5A2 ) and cisplatin-induced cytotoxicity (Fig. 5A3 ). I3C by itself had little cytotoxic effect. Whether enhanced cytotoxicity was due to apoptosis was further investigated. As shown in Fig. 5B , TNF activated caspases as indicated by PARP-cleavage and I3C potentiated TNF-induced activity. The Live and Dead assay indicated that I3C upregulates TNF-induced apoptosis from 7 % to 53 % (Fig. 5C ),
I3C represses TNF-induced
and TUNEL staining showed that TNF-induced apoptosis was enhanced from 8 % with TNF alone to 64 % with I3C plus TNF (Fig. 5D ). In this assay I3C alone exhibited significant toxicity. Nevertheless, all assays together suggest that I3C
enhanced the apoptotic effects of TNF and chemotherapeutic agents.
I3C inhibits constitutive NF-κB activation and proliferation of mononuclear cells
derived from AML patients. It has been reported that NF-κB is constitutively active in AML cells 53 and that the active NF-κB mediates proliferation of cells 35 .
Whether I3C could suppress constitutively active NF-κB in AML cells was investigated in AML cells derived from ten different patients. The cells were treated with I3C nuclear extracts were prepared, and then NF-κB activity was analyzed by EMSA. As shown in Fig. 6A , NF-κB was found to be active in AML cells from most patients, to though variable extents, and I3C suppressed the activation. We also found that the treatment of AML cells with I3C decreased the proliferation of cells (Fig. 6B ).
Discussion
We found that I3C suppressed NF-κB activation induced by various agents irrespective of the cell type. NF-κB inhibition correlated with suppression of IKK and IκBα phosphorylation, ubiquitination, and degradation and with p65 phosphorylation, nuclear translocation, and acetylation. I3C also downregulated NF-κB-regulated reporter gene transcription and gene products involved in cell proliferation, antiapoptosis, and invasion. This led to the potentiation of apoptosis induced by cytokines and chemotherapeutic agents (Fig. 7) .
I3C inhibited NF-κB activation induced by TNF, IL-1β, PMA, LPS, and CSC,
suggesting that I3C must act at a step common to all of these activators. In response to most of these stimuli, NF-κB activation proceeds through sequential activation of IKK, phosphorylation at serines 32 and 36 of IκBα, and ubiquitination at lysines 21 and 22 of IκBα, leading finally to degradation of IκBα and the release of NF-κB 47 . We found that I3C blocks NF-κB activation by inhibiting IKK.
Suppression of TNF-induced NF-κB activation by I3C is consistent with a report by Chinni et al., who showed the suppression of constitutive NF-κB in PC3 cells 4 . They did not, however, report how I3C suppressed constitutive NF-κB activation. changing IKK activity in either cell line 54 . They used up to a 20 times (1 mM) the concentration of I3C as we did to suppress NF-κB. It is unlikely that these differences are due to cell type, as we found that I3C suppressed TNF-induced NF-κB activation in all cell types tested. Perhaps the mechanism of constitutive NF-κB activation differs from that of inducible activation examined in our studies.
Our studies are the first to indicate that I3C also inhibits TNF-induced IKK activation. How IKK is activated is not fully understood, but Akt has been implicated 55 , and I3C has been shown to suppress Akt activation 25, 54 . Thus it is possible that inhibition of TNF-induced IKK activation is due to inhibition of Akt. The activation of Akt has also been shown to be involved in the phosphorylation of the p65 subunit of NF-κB 55 . The suppression of p65 phosphorylation by I3C could also be due to inhibition of Akt.
We showed that I3C inhibited NF-κB-regulated gene transcription and NF-κB-regulated gene products involved in cell proliferation (e.g., cyclin D1 and COX-2);
antiapoptosis (e.g., survivin, IAP1, IAP2, XIAP, Bcl-2, Bfl-1/A1, TRAF1, and FLIP) and invasion (MMP-9). There is no previous report of the regulation of these gene products by I3C. That I3C downregulates cyclin D1 expression and the latter mediates G1/S transition may explain reports indicating that I3C induces of G1/S arrest 3, 4 . The downregulation of the expression of iNOS 23 , PSA 12 , and Bcl-2 4 could also be due to downregulation of NF-κB as described here. 56 . Our results are also consistent with a report that an I3C acid-condensation product mixture sensitizes multidrug resistance gene transfectants to the toxicity of vinblastine and doxorubicin 57 . Whether enhancement of apoptosis by I3C is also mediated through this mechanism, in addition to downmodulation of NF-κB, is unclear at present.
We also found that the expression of such NF-κB-regulated gene products as COX-2 and MMP-9 were downregulated by I3C. These results might explain the anti-invasive and antimetastatic activities assigned to I3C 33,58 . Several chemokines, interleukins, and hematopoietic growth factors are regulated by NF-κB activation 43 . It is possible that immunomodulatory effects of I3C 7, 20 are mediated through the regulation of these cytokines. I3C has been found to prevent cervical cancer in human HPV16 transgenic mice 13 . Because a functional NF-κB binding site exists in the HPV16 long control region 59 , it is possible that its effects against cervical cancer are mediated through suppression of NF-κB as described here.
Constitutively active NF-κB has also been positively correlated with HPV16 E7 Takada Western blot analysis of phospho-p65 and p65 using cytoplasmic extracts (CE).
Jurkat cells were incubated with 50 µM I3C for 24 h and treated with 0.1 nM TNF for the indicated times in minutes. Cytoplasmic extracts were prepared and subjected to Western blot analysis using anti-p65 antibody and phospho-specific anti-p65 antibody. B. Western blot analysis of phospho-p65 and p65 using nuclear extracts (NE). Jurkat cells were incubated with 50 µM I3C for 24 h and treated with 0.1 nM TNF for the indicated times. Nuclear extracts were prepared and subjected to Western blot analysis using anti-p65 and phospho-specific anti-p65 antibodies. 
